Shiga Toxin-Mediated Retrograde Delivery of a Topoisomerase I Inhibitor Prodrug


  • We acknowledge the help from Wolfgang Faigle, Jean-Marc Clavel, and Damarys Loew (mass spectrometry laboratory of the Institut Curie). Our work was supported by funding from the Institut Curie (PIC Vectorisation) and Canceropôle Ile-de-France.


original image

A retrograde strategy: An innovative cancer-cell delivery concept exploits the naturally evolved characteristics of the Shiga toxin B-subunit (STxB) for the intracellular activation of a newly synthesized prodrug at the level of the biosynthetic/secretory pathway (see picture). Retrograde prodrug targeting allows its slow release, which should sustain the presence of the active principle in dividing tumor cells.